Showing 801 - 820 results of 27,040 for search '(( 50 ((mg decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (nn decrease)) ))', query time: 0.78s Refine Results
  1. 801

    The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

    Published 2017
    “…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”
  2. 802
  3. 803

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
  4. 804

    Data_Sheet_1_Sleeping <6.55 h per day was associated with a higher risk of low back pain in adults aged over 50 years: a Korean nationwide cross-sectional study.PDF by Dexin Hu (19710271)

    Published 2024
    “…</p>Conclusion<p>Our findings indicate that shorter sleep duration is a risk factor for LBP in adults aged over 50 years. …”
  5. 805

    HIV-Tat regulates macrophage gene expression in the context of neuroAIDS by Loreto Carvallo (4167607)

    Published 2017
    “…We found that HIV Tat increased expression of C5, APBA1, and BDNF, and decreased CRLF2. …”
  6. 806
  7. 807

    MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01). by Dongyang Xu (303547)

    Published 2013
    “…<p>MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01).…”
  8. 808
  9. 809

    Image1_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  10. 810

    Image2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  11. 811

    Image3_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  12. 812

    Image4_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  13. 813

    Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  14. 814

    3D-Printed Diamond–Titanium Composite: A Hybrid Material for Implant Engineering by Kate Fox (1793524)

    Published 2019
    “…Using this method, we could prepare composite scaffolds of up to 50% diamond, which has never been achieved before. …”
  15. 815

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

    Published 2022
    “…In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC<sub>50</sub> = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC<sub>50</sub> = 18 ± 2 to 107 ± 6 nM). …”
  16. 816

    IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

    Published 2016
    “…Next, by means of IC<sub>50</sub> measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”
  17. 817

    <i>Bbs1</i><sup><i>M390R/M390R</i></sup> mice have decreased hippocampal proliferation. by Thomas K. Pak (10686881)

    Published 2021
    “…At P30, mice were started on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. …”
  18. 818

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  19. 819

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  20. 820